Navigation Links
Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
Date:4/22/2008

DUBLIN, Calif., April 22 /PRNewswire/ -- Microchip Biotechnologies, Inc. (MBI) announces that it has entered into a multi-patent license agreement with GE Healthcare that significantly enhances MBI's intellectual property portfolio supporting the development of lab-on-a-chip devices. The patents cover design and methods for creating integrated fluidic microchip devices.

"Licensing these fundamental patents continues to build our strong intellectual property position in microfluidic devices," said Dr. Stevan Jovanovich, President and CEO of MBI. "Microfluidic devices will play a critical role in next-generation instrumentation that delivers fully-automated, cost-effective bioassay solutions in the life sciences, applied sciences, and molecular diagnostics."

California-based MBI will use the technology licensed from GE Healthcare to develop and commercialize easy to use Sample-To-Answer systems using advanced microfluidic technologies. Microfluidics deals with the behavior, precise control, and manipulation of microliter and nanoliter volumes of fluids to perform life science assays. Microfluidics technologies are essential for development of lab-on-a-chip devices for DNA analysis and molecular diagnostics. Microfluidic devices are smaller, faster and cheaper than the laboratory benchtop instruments that they are designed to replace, and are exquisitely suited for clinical and forensic systems used at the bedside or in the field.

About Microchip Biotechnologies

Microchip Biotechnologies, Inc. is an early-stage privately-held company located in Dublin, California that is developing advanced nanofluidic sample preparation and analytical instrumentation for Life Sciences, Applied Sciences, and Diagnostics markets. These solutions are based on MBI's proprietary "NanoBioProcessor(TM) platform and associated "Microscale-on-Chip-Valves" (MOV(TM)). More details can be found on the Company's website: http://www.microchipbiotech.com.


'/>"/>
SOURCE Microchip Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
2. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
3. Team develops energy-efficient microchip
4. Quick microchip test for dangerous antibiotic resistant bacteria
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
7. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
8. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
9. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
10. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
11. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... innovators, engineers, and scientists from around the world, was today awarded the "Best ... program is based entirely on merit and decided upon by a dedicated team ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... spanning the full spectrum of drug and device development, and Prism Clinical ... companies and clinicians, today announced Verified Clinical Trials (VCT) has been ...
(Date:1/19/2017)...  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a ... operable and inoperable solid tumor cancers, announced today that ... NW Bio, will present at the Phacilitate Immunotherapy World ... Regency Hotel in Miami, Florida . ... "New Therapeutic Approaches – Expanding the Reach of Cancer ...
Breaking Biology Technology:
(Date:1/18/2017)... MedNet Solutions , an innovative ... spectrum of clinical research, is proud to announce ... the organization in terms of corporate growth, outside ... and services. The company,s exceptional achievements can be ... iMedNet ™ – MedNet,s ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... office of the future.  1,000 participants were simply asked which ... months which we may consider standard issue.  Insights on what ... 2017 were also gathered from futurists and industry leaders including ... James Canton .  Some of ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
Breaking Biology News(10 mins):